Discovery of novel biomarkers for Epstein Barr Virus (EBV) infection related cancers - HL and NK/T lymphomas (Old ID 26515)

NIH National Cancer Institute
Role

Principal Investigator

Description

There is a large body of evidence indicating that Epstein-Barr virus (EBV) actively contributes to the pathogenesis of multiple tumours. We hypothesize that the antibody response to EBV is altered in infection-related cancers. We are comprehensively assessing the antibody response to EBV in individuals with and without cancer (cases and controls) using our proprietary EBV proteome array, to identify an antibody signature which predicts cancer risk. The ultimate goal is an immunodiagnostic test to identify individuals in the general population who are at high risk of developing infection-related cancers. Extending previous studies, we will probe defined samples from Hodgkin Lymphoma and NK/T cell study provided by colleageus at NIH/NCI to define IgA and IgG antibody repertoires.

Date

09 Apr 2019 - 19 Mar 2021

Project Type

CONTRACT_RESEARCH

Keywords

EBV infection-related cancer

Funding Body

NIH National Cancer Institute

Amount

74997

Project Team

Carla Proietti;Yomani Sarathkumara